Kiniksa Pharmaceuticals, Ltd. (KNSA)
USD 21.4
(-2.08%)
USD 21.4
(-2.08%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 13.3 Million | 5.8 Million | -126.29 Million | -136.53 Million | -158.36 Million | -81.01 Million |
| Net Income | 14.08 Million | 183.36 Million | -157.92 Million | -161.38 Million | -161.86 Million | -103.22 Million |
| Depreciation & Amortization | 2.1 Million | 2.4 Million | 2.35 Million | 2.4 Million | 2.06 Million | 286 Thousand |
| Deferred income taxes | -33.78 Million | -185.49 Million | 11 Thousand | 4.36 Million | -3.15 Million | -978 Thousand |
| Stock-based compensation | 27.14 Million | 25.12 Million | 25.17 Million | 20.87 Million | 15.08 Million | 5.7 Million |
| Change in working capital | 1.35 Million | -22.57 Million | 689 Thousand | -4.31 Million | -17.02 Million | 18.32 Million |
| Other non-cash items | 2.39 Million | 2.99 Million | 3.39 Million | 1.52 Million | 6.53 Million | -1.12 Million |
| Investing Cash Flow | -29.55 Million | -8.07 Million | 128.63 Million | -23.44 Million | 49.21 Million | -239.19 Million |
| Investments in PPE | -130 Thousand | -105 Thousand | -20.41 Million | -283 Thousand | -3.2 Million | -5.29 Million |
| Acquisitions | 29.42 Million | 91 Thousand | 20 Million | 23.16 Million | -52.41 Million | - |
| Investment purchases | -204.93 Million | -135.86 Million | -157.25 Million | -430.21 Million | -488.77 Million | -402 Million |
| Sales/Maturities of investments | 175.5 Million | 127.8 Million | 306.3 Million | 407.05 Million | 541.19 Million | 168.1 Million |
| Other Investing Activities | -29.42 Million | -7.97 Million | -20 Million | -23.16 Million | 52.41 Million | -233.9 Million |
| Financing Cash Flow | 1.49 Million | 2.51 Million | 5.88 Million | 227.08 Million | 84.1 Million | 346.73 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -2.2 Million | -901 Thousand | 5.88 Million | 6.55 Million | - | - |
| Common Stock Issuance | 1.49 Million | 3.41 Million | 5.88 Million | 227.08 Million | 84.1 Million | 159.19 Million |
| Other Financing Activities | 2.2 Million | -901 Thousand | 5.88 Million | 227.08 Million | 84.1 Million | 187.54 Million |
| Accounts receivables | -950 Thousand | -8.67 Million | -3.91 Million | - | - | - |
| Accounts payables | 347 Thousand | 6.03 Million | 1.36 Million | -4.96 Million | -4.7 Million | 8.82 Million |
| Inventory | -9.52 Million | -17.92 Million | -3.67 Million | - | - | - |
| Other working capital | 11.47 Million | -2 Million | 6.9 Million | 654 Thousand | -12.32 Million | 9.5 Million |
| Cash at beginning of period | 122.71 Million | 122.47 Million | 114.24 Million | 47.13 Million | 72.18 Million | 45.66 Million |
| Cash at end of period | 107.95 Million | 122.71 Million | 122.47 Million | 114.24 Million | 47.13 Million | 72.18 Million |
| Capital Expenditure | -130 Thousand | -105 Thousand | -20.41 Million | -283 Thousand | -3.2 Million | -5.29 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -14.76 Million | 245 Thousand | 8.22 Million | 67.11 Million | -25.04 Million | 26.52 Million |
| Free Cash Flow | 13.17 Million | 5.7 Million | -146.71 Million | -136.81 Million | -161.57 Million | -86.3 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -12.69 Million | -3.9 Million | -17.7 Million | 14.08 Million | 25.23 Million | -13.85 Million |
| Depreciation & Amortization | 399 Thousand | 430 Thousand | 466 Thousand | 2.1 Million | 236 Thousand | 603 Thousand |
| Deferred income taxes | -3.63 Million | 10.56 Million | 4.36 Million | -33.78 Million | -25.7 Million | 10.28 Million |
| Stock-based compensation | 7.82 Million | 7.36 Million | 7.2 Million | 27.14 Million | 7.77 Million | 6.78 Million |
| Change in working capital | 5.6 Million | -9.91 Million | 8.57 Million | 1.35 Million | -3.96 Million | 11.01 Million |
| Other non-cash items | 267 Thousand | 19.15 Million | 2.76 Million | 2.39 Million | 749 Thousand | 2.14 Million |
| Investing Cash Flow | -6.34 Million | -46.79 Million | 25.52 Million | -29.55 Million | -14.89 Million | -12.27 Million |
| Investments in PPE | - | - | -84 Thousand | -130 Thousand | -56 Thousand | -16 Thousand |
| Acquisitions | -25 Thousand | 25 Thousand | - | 29.42 Million | 14.83 Million | 12.26 Million |
| Investment purchases | -54.48 Million | -89.26 Million | -36.27 Million | -204.93 Million | -60.81 Million | -53.08 Million |
| Sales/Maturities of investments | 48.13 Million | 42.44 Million | 61.88 Million | 175.5 Million | 45.97 Million | 40.82 Million |
| Other Investing Activities | 25 Thousand | -46.79 Million | 25.6 Million | -29.42 Million | -14.83 Million | -12.26 Million |
| Financing Cash Flow | 6.68 Million | -178 Thousand | 3.61 Million | 1.49 Million | 695 Thousand | 552 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -2.71 Million | -1.31 Million | -381 Thousand | -2.2 Million | -262 Thousand | -1.1 Million |
| Common Stock Issuance | -3.43 Million | -178 Thousand | 3.61 Million | 1.49 Million | 695 Thousand | 552 Thousand |
| Other Financing Activities | 9.4 Million | 1.13 Million | -381 Thousand | 2.2 Million | 262 Thousand | 1.1 Million |
| Accounts receivables | -4.43 Million | -4.45 Million | 5.27 Million | -950 Thousand | -18.22 Million | 21.6 Million |
| Accounts payables | 911 Thousand | 1.72 Million | -2.66 Million | 347 Thousand | 7.23 Million | 364 Thousand |
| Inventory | 6.17 Million | -7.58 Million | 3.84 Million | -9.52 Million | -5.53 Million | -1.62 Million |
| Other working capital | 2.95 Million | 397 Thousand | 2.12 Million | 11.47 Million | 12.56 Million | -9.33 Million |
| Cash at beginning of period | 99.27 Million | 141.07 Million | 107.95 Million | 122.71 Million | 117.82 Million | 112.56 Million |
| Cash at end of period | 97.37 Million | 99.27 Million | 141.07 Million | 107.95 Million | 107.95 Million | 117.82 Million |
| Capital Expenditure | - | - | -84 Thousand | -130 Thousand | -56 Thousand | -16 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -1.89 Million | -41.8 Million | 33.12 Million | -14.76 Million | -9.87 Million | 5.26 Million |
| Free Cash Flow | -2.23 Million | 5.16 Million | 3.9 Million | 13.17 Million | 4.26 Million | 16.97 Million |
ALDRV
ENGINERSIN
5471
BMEA
RRX
TRT